Alnylam Pharmaceuticals, Inc.
Alnylam is the Leading RNAi Therapeutics Company. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Alnylam is derived from “Alnilam,” the bright center star in the constellation Orion’s belt, which has been used by navigators for thousands of years and symbolizes our passion for discovery.
Medicines based on RNAi work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. In doing so, RNAi therapeutics work “upstream” of most other classes of medicines, such as small molecules and monoclonal antibodies, by targeting the “root” genetic cause of a disease rather than its symptoms. To learn more about our science, click here.RNAi is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
Vision, Mission, and Values
Harnessing a revolution in biology for human health®.
Build a top-tier, global, independent biopharmaceutical company founded on RNAi.
Our Core Values
Commitment to People, Innovation & Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.
Diversity, Equity & Inclusion at Alnylam
At Alnylam, we believe that our long-term success and ability to deliver medicines to patients requires a diverse, equitable and inclusive workforce. We are committed to building an environment where employees are enabled to achieve their full potential. By empowering employees to bring their unique differences to work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
We promote an environment of diversity, equity and inclusiveness at Alnylam, regardless of race, gender, sexual orientation, religion, ethnicity, national origin, physical disability, or age.
Alnylam’s core values include a Commitment to People and an Open Culture. We put diversity, equity and inclusion at the forefront of Alnylam’s core values to exhibit the same dedication to our people as we do to pioneering new medicines.
We’re proud of the progress we’ve made and have been recognized for our leadership by Bloomberg, who selected us to their prestigious Gender-Equity Index for 2021, and by the Eos Foundation in 2020 for gender parity and fair representation for Women of Color (WOC) rankings at Executive and Board Leadership levels.
We seek to:
- Act as a globally inclusive and bias-free company
- Ensure that we attract and retain diverse talent from all backgrounds
- Maintain a culturally aware environment through employee development and networking
- Use diversity among employees to better understand the varying needs of our patient population
- Develop internal and external partnerships with key groups to influence policies
To make Alnylam a global leader in Diversity, Equity & Inclusion.
To build a diverse, equitable and inclusive workforce that fosters an environment where employees feel empowered to achieve their full potential.
By empowering employees to bring their unique differences to work we make the business stronger which enables us to bring groundbreaking medicines to patients.
Our Core Values
- Sense of Urgency
- Open Culture
- Commitment to People
- Innovation & Discovery
- Passion for Excellence
Stemming from the core values of Alnylam, our approach to corporate responsibility embodies our “Challenge Accepted” philosophy. Our corporate responsibility mission statement—“Accepting challenges to improve the health of humanity”—helps articulate how we approach our work each day. It describes our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good.
Go in depth—download our 2020 Corporate Responsibility Summary and check out our most recent Corporate Responsibility news.
Four core beliefs guide our ongoing corporate responsibility work:
- We believe in the noble pursuit of working to improve the health of humanity.
- We believe science has the power to solve our many complex social, health, and environmental challenges.
- We believe diverse, inclusive, and equitable environments are essential for achieving breakthroughs.
- We believe all communities deserve access to health solutions and social support.
These beliefs inform our Corporate Responsibility as a company, and as advocates for five key areas of focus: patients, science, employees, communities, and our planet. Each of these has a guiding imperative, dedicated leadership team, and accountabilities to track and manage our impact.